CHI Drug Discovery Chemistry

We are proud to announce that we will be sponsoring the Cambridge Healthtech Institute’s 12th Annual Drug Discovery Chemistry conference at the Sheraton San Diego Hotel & Marina (April 23-27, 2017)

Our presentation

Prediction of Drug Efficiency: Aptuit’s Experience in CNS Drug Design & Discovery
Presenter: Alfonso Pozzan, Ph.D., Manager & Principal Scientific Investigator, Computational Chemistry, Aptuit
Presentation date and time: Monday 24th April at 9:10am

Abstract
The selection of high-quality drug candidates is recognized as the most important decision in Drug Discovery. In ‘97, Lipinski paved the way towards a more rational use of physicochemical descriptors to predict the quality of such molecules. As an evolution of this concept, we have introduced in 2010 an in vitro/in vivo Drug Efficiency (Deff) coefficient and now an in silico Deff predictor to be used during the Drug Design phase

Our attending experts

To request a meeting with one of the scientific staff please contact us at contactus@aptuit.com

APTUIT ANNOUNCES EXPANSION OF COMPOUND LIBRARY

Logo AptuitGreenwich, CT, November 30, 2016Part of 5m$ Investment in Integrated Drug Discovery Capabilities

Aptuit, LLC today announced that it had successfully completed the expansion of their lead-like screening library. An additional 150,000 novel compounds have increased the Screening Collection to over 400,000. The new compounds were carefully selected to broaden the hit discovery capabilities of the company. This expansion, complemented by new robotics and compound management infrastructure, is part of an additional $5m investment in integrated discovery services.

The expanded collection provides enhanced chemical diversity and coverage of chemical space, compliance with lead-likeness criteria, improved physico-chemical properties, and optimal medicinal chemistry tractability. Expected benefits extend across a wide range of target classes and anticipated modes of action.

Dr Stephan Fasler, CEO of Aptuit (Switzerland) AG stated: “I am delighted by the additional investment. This further increases our ability to identify novel leads, and constitutes an industry leading solution for our BioPharma customers”.

Aptuit CEO Dr. Jonathan Goldman stated, “We continue to see strong demand for integrated discovery programs that result in high quality druggable candidates. Our additional investment in compounds and automation will ensure we create the best drug candidates whilst controlling costs. As the leading Partner Research Organization we continue to innovate in best in class integrated discovery and development”.

Press release: http://news.aptuit.com/aptuit-announces-expansion-of-compound-library

About Aptuit, LLC
Aptuit provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland.

Aptuit Holdings, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world’s leading private equity investors.

For more information, please visit www.aptuit.com

Aptuit announces acquisition of Exquiron Biotech AG

Logo AptuitGreenwich, CT, April 21st, 2016Aptuit, LLC today announced that it has acquired Exquiron Biotech AG to meet customer demand for fully integrated outsourced discovery services. Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions.

Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.

Dr. Jonathan Goldman, Chief Executive Officer of Aptuit stated, “Aptuit specializes in the discovery of small molecules across a wide range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery. In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and very high quality delivery of a research program from target to high quality candidate nomination. We expect our customers to benefit from improved probability of candidate nomination, with reductions in time and cost.

Customers value our unique capabilities in integrated discovery and integrated development. We are delighted to combine our core scientific expertise in discovery with the early discovery capabilities of our Exquiron colleagues.”

Dr. Goldman explained that Aptuit’s best in class integrated discovery solutions are unique in the marketplace.

“Our company is experiencing increased demand for integrated services from gene up to candidate nomination, and from candidate to IND. We are delighted to respond by expanding our capabilities”.

Dr. Stephan Fasler, CEO and founder of Exquiron added, “We are excited to join Aptuit, a highly respected leader in the discovery and development CRO sector. Our customers can now combine our expertise in assay development and high throughput screening with the ability to translate seamlessly to candidate nomination and IND filing. Exquiron and Aptuit share a culture and commitment to scientific excellence, making this a very good fit”

Press release: http://info.aptuit.com/aptuit-acquires-exquiron
FAQs: http://info.aptuit.com/aptuit-acquires-exquiron-faqs

About Aptuit, LLC
Aptuit, LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and now Switzerland. Aptuit, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world’s leading private equity investors.
For more information, please visit www.aptuit.com

About Exquiron Biotech AG
Exquiron was founded in 2013 and are dedicated to state-of-the-art hit identification and validation services for their customers. With a combined team track record of over 60 years in early stage drug discovery and a high level of expertise and flexibility, they help their customers advance their programs and generate added value in the areas of pharmaceutical drug discovery and nutraceuticals.

SAMDI Tech, Inc and Exquiron Announce Partnership Agreement

CHICAGO, IL – February 8, 2015 — SAMDI Tech and Exquiron are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Exquiron to mutually promote their respective services in Europe and North America. The two companies aim to offer hit discovery, hit profiling, and assay development services, combining their expertise to the benefit of their clients. The partnership provides SAMDI Tech’s clients the added benefit of Exquiron’s broad assay capabilities and lead-like, 250,000 compound collection as well as access of SAMDI Tech’s exclusive label-free, MALDI-TOF capabilities to Exquiron and its clients.

“I am excited to partner with Exquiron as our technology is innovative to the discovery field and coupled with Exquiron’s additional assay capabilities and compound collection we can offer a comprehensive solution to our clients.

SAMDI is a unique label-free assay platform for measurement of complex biochemical activity.

Stephan Fasler Ph.D., CEO of Exquiron commented “We have previously collaborated with SAMDI Tech; the company has been our first choice for entering into this partnership. We are impressed by the novelty and quality of SAMDI Tech’s label-free assay technology, which, coupled with their excellent assay development services, renders SAMDI Tech a company to absolutely work with.”

About SAMDI Tech, Inc:

SAMDI Tech, Inc, headquartered in Chicago, IL is a contract research organization supporting discovery research. SAMDI’s pioneering technology combines surface chemistry and MALDI mass spectrometry in both 384 and 1536 format for rapid assay development, high-throughput screening, and peptide substrate discovery and supports both biotech and large pharmaceutical companies. Learn more about SAMDI Tech at www.samditech.com

About Exquiron Biotech AG:

Exquiron, headquartered in Reinach BL, Switzerland, is a company dedicated to contract research in early stage drug discovery. Its services span from assay development for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Exquiron’s team brings extensive skills and know-how in all areas of the hit identification process, including broad target class coverage, applicable technologies, data processing and evaluation.

Enamine Provides Exquiron with Large Novel Diverse Screening Compound Library

June 3, 2013

KIEV, Ukraine and BASEL, Switzerland, June 3rd 2013 – Enamine Ltd, a leading provider of screening compounds, chemical building blocks and discovery services, and Exquiron Biotech AG, a company specializing in early stage drug discovery services, today announced a multiyear collaboration under which Enamine will provide a carefully selected, novel diverse screening compound library. This library will be made available by Exquiron to screening clients for hit discovery projects.

The library provided by Enamine is a great asset for discovery programs as it includes a high number of diverse drug-like compounds. Exquiron and its clients will also have access to Enamine’s full range of chemistry expertise, for post screening follow-up.

Dr. Serge Parel, VP Chemistry and Research Informatics, Exquiron, commented: “Offering high quality chemistry to our clients is crucial. We are impressed by the quality and novelty of Enamine’s compounds, coupled with their logistics and support services. Together we can offer clients excellent value.

“We are pleased that Exquiron has chosen to work with us. We see this as confirmation of the quality of our chemistry and services, and hope that our collaboration will contribute to Exquiron’s success,” added Michael Bossert, Head of Strategic Alliances, Enamine.

About Exquiron
Exquiron is a newly formed Swiss company with service offerings in early stage drug discovery. Services span from development of hit identification and profiling assays to compound selection, high throughput screening, hit profiling and characterization, and SAR expansion. The Exquiron team brings extensive skills and know-how in all areas of hit discovery, including target class coverage, applicable technologies, data evaluation and reporting, and project management.
www.exquiron.com

About Enamine
Established in Kiev in 1991, Enamine is a leading provider of innovative screening libraries, building blocks, fragments, and comprehensive chemistry support in hit discovery and integrated drug discovery services. Enamine’s design and synthesis capabilities allow the addition of more than 250,000 new organic compounds to its catalogue each year. Enamine offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds and building blocks. Enamine serves the pharmaceutical, agrochemical, cosmetic, nutritional and petrochemical industries.
www.enamine.net

Contacts:

Enamine
Michael Bossert
Head Strategic Alliances
E: m.bossert(at)enamine.net
T: +38 044 537 32 18

Exquiron
Serge P. Parel
VP Chemistry and Research Informatics
E: sparel(at)exquiron.com
T: +41 61 716 85 77